Syros Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Syros Pharmaceuticals's earnings have been declining at an average annual rate of -12.3%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 0.8% per year.
Key information
-12.3%
Earnings growth rate
29.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -0.8% |
| Return on equity | n/a |
| Net Margin | -25,340.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout
Jul 02Syros Pharmaceuticals: Rising Despite Dilution, A Must Look
Jan 14Syros Pharmaceuticals: A Major Vote Of Confidence From Insiders
Sep 20Syros gets FDA orphan drug designation for pancreatic cancer treatment SY-5609
Sep 13Syros Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Revenue & Expenses Breakdown
How Syros Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -98 | 23 | 0 |
| 30 Jun 24 | 4 | -132 | 25 | 0 |
| 31 Mar 24 | 7 | -144 | 27 | 0 |
| 31 Dec 23 | 10 | -165 | 28 | 0 |
| 30 Sep 23 | 9 | -105 | 30 | 0 |
| 30 Jun 23 | 9 | -95 | 30 | -58 |
| 31 Mar 23 | 12 | -93 | 30 | 0 |
| 31 Dec 22 | 15 | -95 | 29 | 0 |
| 30 Sep 22 | 23 | -114 | 28 | 27 |
| 30 Jun 22 | 25 | -109 | 26 | 112 |
| 31 Mar 22 | 24 | -97 | 24 | 80 |
| 31 Dec 21 | 23 | -87 | 23 | 100 |
| 30 Sep 21 | 21 | -93 | 22 | 102 |
| 30 Jun 21 | 20 | -86 | 22 | 93 |
| 31 Mar 21 | 18 | -81 | 22 | 82 |
| 31 Dec 20 | 15 | -84 | 21 | 76 |
| 30 Sep 20 | 10 | -74 | 22 | 61 |
| 30 Jun 20 | 7 | -74 | 22 | 60 |
| 31 Mar 20 | 4 | -76 | 22 | 60 |
| 31 Dec 19 | 2 | -75 | 21 | 58 |
| 30 Sep 19 | 2 | -74 | 19 | 59 |
| 30 Jun 19 | 2 | -70 | 18 | 56 |
| 31 Mar 19 | 2 | -64 | 17 | 52 |
| 31 Dec 18 | 2 | -62 | 16 | 50 |
| 30 Sep 18 | 1 | -60 | 16 | 47 |
| 30 Jun 18 | 1 | -58 | 15 | 44 |
| 31 Mar 18 | 0 | -57 | 15 | 43 |
| 31 Dec 17 | 1 | -54 | 14 | 42 |
| 30 Sep 17 | 1 | -50 | 13 | 39 |
| 30 Jun 17 | 1 | -50 | 12 | 40 |
| 31 Mar 17 | 1 | -51 | 11 | 39 |
| 31 Dec 16 | 0 | -51 | 10 | 38 |
| 30 Sep 16 | 0 | -52 | 10 | 38 |
| 30 Jun 16 | 0 | -48 | 9 | 33 |
| 31 Mar 16 | 0 | -41 | 7 | 29 |
| 31 Dec 15 | 0 | -35 | 6 | 24 |
| 30 Sep 15 | 0 | -28 | 4 | 19 |
| 31 Dec 14 | 0 | -16 | 3 | 11 |
Quality Earnings: SYRS is currently unprofitable.
Growing Profit Margin: SYRS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SYRS is unprofitable, and losses have increased over the past 5 years at a rate of 12.3% per year.
Accelerating Growth: Unable to compare SYRS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SYRS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: SYRS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.